GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Selling, General, & Admin. Expense

AEterna Zentaris (AEterna Zentaris) Selling, General, & Admin. Expense : $8.72 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. AEterna Zentaris's selling, general, & admin. expense for the three months ended in Dec. 2023 was $2.59 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was $8.72 Mil.


AEterna Zentaris Selling, General, & Admin. Expense Historical Data

The historical data trend for AEterna Zentaris's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Selling, General, & Admin. Expense Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.83 5.89 7.27 8.23 8.72

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 2.31 2.03 1.79 2.59

Competitive Comparison of AEterna Zentaris's Selling, General, & Admin. Expense

For the Biotechnology subindustry, AEterna Zentaris's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Selling, General, & Admin. Expense falls into.



AEterna Zentaris Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEterna Zentaris  (NAS:AEZS) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


AEterna Zentaris Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (AEterna Zentaris) Business Description

Industry
Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.